Skip to main content

Table 4 The Incidence of Carriage and Healthcare-Associated Infection of MDRO per 1000 Patient-Days were Determined in the Pre-intervention Period and During the Intervention Period

From: Implementation of human factors engineering approach to improve environmental cleaning and disinfection in a medical center

Ā Ā 

The incidence of MDRO per 1000 patient-days

Ā 
Ā 

n

Pre-intervention perioda

Intervention periodb

P

Carriage

ā€ƒOverall

28

4.1 (564/136794)

3.6 (507/140860)

.03

ā€ƒā€ƒVRE

Ā 

1.8 (253/136794)

1.3 (184/140860)

< .001

ā€ƒā€ƒMRSA

Ā 

1.3 (178/136794)

1.2 (171/140860)

.55

ā€ƒā€ƒCRABC

Ā 

1.0 (133/136794)

1.1 (152/140860)

.41

ā€ƒGeneral wards

19

3.7 (421/114141)

3.4 (403/117894)

.29

ā€ƒā€ƒVRE

Ā 

1.8 (209/114141)

1.3 (152/117894)

< .001

ā€ƒā€ƒMRSA

Ā 

1.2 (136/114141)

1.2 (147/117894)

.75

ā€ƒā€ƒCRABC

Ā 

0.7 (76/114141)

0.9 (104/117894)

.07

ā€ƒICUs

9

6.3 (143/22653)

4.5 (104/22966)

.01

ā€ƒā€ƒVRE

Ā 

1.9 (44/22653)

1.4 (32/22966)

.19

ā€ƒā€ƒMRSA

Ā 

1.9 (42/22653)

1.0 (24/22966)

.03

ā€ƒā€ƒCRABC

Ā 

2.5 (57/22653)

2.1 (48/22966)

.39

Healthcare-associated infection

ā€ƒOverall

28

0.3 (47/136794)

0.4 (62/140860)

.23

ā€ƒGeneral wards

19

0.3 (30/114141)

0.4 (44/117894)

.17

ā€ƒICUs

9

0.8 (17/22653)

0.8 (18/22966)

.97

  1. NOTE. MDRO multiple-drug resistant organism, including vancomycin-resistant enterococci (VRE), methicillin-resistant Staphylococcus aureus (MRSA), and carbapenem-resistant Acinetobacter baumannii complex (CRABC)
  2. aJuly 2016 to January 2017
  3. bMarch 2017 to September 2017